Compare Logitech International SA (LOGI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Sana Biotechnology Inc — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Logitech International SA is far larger — about 17.3× Sana Biotechnology Inc's market cap, and Logitech International SA pays a 1.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Sana Biotechnology Inc for 23 Days on average.
| LOGI | SANA | |
|---|---|---|
Market Cap | $14.46B | $836.71M |
Volume | 349,547 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $126.69 | $5.92 |
52-Week Low | $85.84 | $2.68 |
Typical Hold Time | 92 Days | 23 Days |
Enterprise Value | $12.79B | $749.96M |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with neutral technical indicators and mixed analyst sentiment. The company demonstrates strong profitability with 45.13% gross margins and 35.29% ROE, while recent earnings beats and new product launches including Zone Vibe Pro headsets and gaming partnerships signal innovation momentum. Cash flow trends show operational strength despite recent net outflow.
Outlook remains balanced with 5.3% upside to consensus price target of $107, though analyst ratings are evenly split. Key risks include chip shortage challenges cited by management and competitive pressures in the peripheral market. Revenue growth acceleration to $4.9B projected for 2026 supports potential valuation expansion if execution continues.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
